title: Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
abstract: Visualisation of primary prostate cancer, its relapse and its metastases is a clinically relevant problem despite the availability of state-of-the-art methods such as CT, MRI, transrectal ultrasound and fluorine-18 fluorodeoxyglucose positron emission tomography ((18)F-FDG PET). The aim of this study was to evaluate the efficacy of carbon-11 acetate and (18)F-FDG PET in the detection of prostate cancer and its metastases. Twenty-five patients were investigated during the follow-up of primary prostate cancer, suspected relapse or metastatic disease using (11)C-acetate PET; 15 of these patients were additionally investigated using (18)F-FDG PET. Fourteen patients were receiving anti-androgen treatment at the time of the investigation. Lesions were detected in 20/24 (83%) patients using (11)C-acetate PET and in 10/15 (75%) patients using (18)F-FDG PET. Based on the results of both PET scans, one patient was diagnosed with recurrent lung cancer. Median (18)F-FDG uptake exceeded that of (11)C-acetate in distant metastases (SUV =3.2 vs 2.3). However, in local recurrence and in regional lymph node metastases, (11)C-acetate uptake (median SUVs =2.9 and 3.8, respectively) was higher than that of (18)F-FDG (median SUVs =1.0 and 1.1, respectively). A positive correlation was observed between serum PSA level and both (11)C-acetate uptake and (18)F-FDG uptake. (11)C-acetate seems more useful than (18)F-FDG in the detection of local recurrences and regional lymph node metastases. (18)F-FDG, however, appears to be more accurate in visualising distant metastases. There may be a role for combined (11)C-acetate/(18)F-FDG PET in the follow-up of patients with prostate cancer and persisting or increasing PSA.
authors.affiliation: Department of Nuclear Medicine, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany. efricke@hdz-nrw.de
authors.forename: E
authors.initials: E
authors.lastname: Fricke
authors.forename: S
authors.initials: S
authors.lastname: Machtens
authors.forename: M
authors.initials: M
authors.lastname: Hofmann
authors.forename: J
authors.initials: J
authors.lastname: van den Hoff
authors.forename: S
authors.initials: S
authors.lastname: Bergh
authors.forename: T
authors.initials: T
authors.lastname: Brunkhorst
authors.forename: G J
authors.initials: GJ
authors.lastname: Meyer
authors.forename: J H
authors.initials: JH
authors.lastname: Karstens
authors.forename: W H
authors.initials: WH
authors.lastname: Knapp
authors.forename: A R
authors.initials: AR
authors.lastname: Boerner
mesh_terms: D000085:Acetates; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000556:secondary; D002244:Carbon; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000000981:diagnostic imaging*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000473:pathology; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed / Q000379:methods*
chemical_list: D000085:Acetates; D019275:Radiopharmaceuticals; C438206:carbon-11 acetate; D019788:Fluorodeoxyglucose F18; D002244:Carbon; D017430:Prostate-Specific Antigen